The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Sacituzumab tirumotecan (sac-TMT) as first-line treatment for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC): Initial results from the phase II OptiTROP-Breast05 study.
 
Yongmei Yin
No Relationships to Disclose
 
Quchang Ouyang
No Relationships to Disclose
 
Min Yan
No Relationships to Disclose
 
Jian Zhang
No Relationships to Disclose
 
Lihua Song
No Relationships to Disclose
 
Wei Li
No Relationships to Disclose
 
Yuanting Gu
No Relationships to Disclose
 
Xiaoyu Liu
No Relationships to Disclose
 
Jingfen Wang
No Relationships to Disclose
 
Xiaojia Wang
No Relationships to Disclose
 
Xi Yan
No Relationships to Disclose
 
Jin Yang
No Relationships to Disclose
 
Weipeng Zhao
No Relationships to Disclose
 
Yuee Teng
No Relationships to Disclose
 
Tingjing Yao
No Relationships to Disclose
 
Zhengkui Sun
No Relationships to Disclose
 
Xiaoping Jin
Employment - Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Leadership - Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
 
Yina Diao
Employment - Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Leadership - Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
 
Gesha Liu
Employment - Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
 
Junyou Ge
Employment - Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Leadership - Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.